Evidence map›Paper›PMID 40145384›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025

Amyloid PET predicts longitudinal functional and cognitive trajectories in a heterogeneous cohort.

Kyan Younes, Emily Johns, Christina B Young, Gabriel Kennedy, Shubhabrata Mukherjee, Hillary A Vossler, Joseph Winer, Karly Cody, Victor W Henderson, Kathleen L Poston and 33 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Review
  3. Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  4. Prognostic value of plasma %p-tau217 in cognitively unimpaired older adults.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  5. Complex interplay of astrogliosis and pathology in preclinical Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  6. Article
  7. Review
  8. Observational
  9. Comparison of amyloid PET acquired through standardized and unstandardized protocols.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  10. Review
  11. Amyloid PET predicts longitudinal functional and cognitive trajectories in a heterogeneous cohort.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

43 authors.

Kyan YounesDepartment of Neurology and Neurological Sciences, Stanford University, Palo Alto, California, USA.
Emily JohnsDepartment of Neurology and Neurological Sciences, Stanford University, Palo Alto, California, USA.
Christina B YoungDepartment of Neurology and Neurological Sciences, Stanford University, Palo Alto, California, USA.
Gabriel KennedyDepartment of Neurology and Neurological Sciences, Stanford University, Palo Alto, California, USA.
Shubhabrata MukherjeeDepartment of Medicine, The University of Washington, Seattle, Washington, USA.
Hillary A VosslerDepartment of Neurology and Neurological Sciences, Stanford University, Palo Alto, California, USA.
Joseph WinerDepartment of Neurology and Neurological Sciences, Stanford University, Palo Alto, California, USA.
Karly CodyDepartment of Neurology and Neurological Sciences, Stanford University, Palo Alto, California, USA.
Victor W HendersonDepartment of Neurology and Neurological Sciences, Stanford University, Palo Alto, California, USA.
Kathleen L PostonDepartment of Neurology and Neurological Sciences, Stanford University, Palo Alto, California, USA.
Tobey J BetthauserWisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Bill BevisWisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
William M BrooksUniversity of Kansas Alzheimer's Disease Center, University of Kansas Medical Center, Kansas City, Kansas, USA.
Jeffrey M BurnsUniversity of Kansas Alzheimer's Disease Center, University of Kansas Medical Center, Kansas City, Kansas, USA.
Stephen A CoombesFlorida Alzheimer's Disease Research Center, University of Florida, Gainesville, Florida, USA.
Charles DeCarliAlzheimer's Disease Research Center, University of California Davis Health, Davis, California, USA.
Frank P DiFilippoCleveland Alzheimer's Disease Research Center, Cleveland, Ohio, USA.
Ranjan DuaraFlorida Alzheimer's Disease Research Center, University of Florida, Gainesville, Florida, USA.
Audrey P FanAlzheimer's Disease Research Center, University of California Davis Health, Davis, California, USA.
Laura E GibbonsDepartment of Medicine, The University of Washington, Seattle, Washington, USA.
Todd GoldeFlorida Alzheimer's Disease Research Center, University of Florida, Gainesville, Florida, USA.
Sterling C JohnsonWisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Rebecca J LeppingUniversity of Kansas Alzheimer's Disease Center, University of Kansas Medical Center, Kansas City, Kansas, USA.
James LeverenzCleveland Alzheimer's Disease Research Center, Cleveland, Ohio, USA.
Sean McDougallAlzheimer's Disease Research Center, University of California Davis Health, Davis, California, USA.
Emily RogalskiHealthy Aging & Alzheimer's Research Care (HAARC) Center, Department of Neurology, University of Chicago, Chicago, Illinois, USA.
Elizabeth SandersDepartment of Medicine, The University of Washington, Seattle, Washington, USA.
Joshua PasayeMesulam Center for Cognitive Neurology and Alzheimer's Disease, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Jaiashre SridharMesulam Center for Cognitive Neurology and Alzheimer's Disease, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Andrew J SaykinIndiana Alzheimer's Disease Research Center, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Anjali SridharanWisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Russell SwerdlowUniversity of Kansas Alzheimer's Disease Center, University of Kansas Medical Center, Kansas City, Kansas, USA.
Emily H TrittschuhDepartment of Psychiatry and Behavioral Science, University of Washington, Seattle, Washington, USA.
David VaillancourtFlorida Alzheimer's Disease Research Center, University of Florida, Gainesville, Florida, USA.
Eric VidoniUniversity of Kansas Alzheimer's Disease Center, University of Kansas Medical Center, Kansas City, Kansas, USA.
Wei-En WangUniversity of Kansas Alzheimer's Disease Center, University of Kansas Medical Center, Kansas City, Kansas, USA.
Jesse MezDepartment of Neurology, Boston University, Boston, Massachusetts, USA.
Timothy J HohmanVanderbilt Memory and Alzheimer's Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Duygu TosunDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, California, USA.
Sarah BiberDepartment of Epidemiology, National Alzheimer's Coordinating Center, University of Washington, Seattle, Washington, USA.
Walter A KukullDepartment of Epidemiology, National Alzheimer's Coordinating Center, University of Washington, Seattle, Washington, USA.
Paul K CraneDepartment of Medicine, The University of Washington, Seattle, Washington, USA.
Elizabeth C MorminoDepartment of Neurology and Neurological Sciences, Stanford University, Palo Alto, California, USA.

Funding

National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)U24AG021886 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI TATIANA M. FOROUD · 2002 to 2026
$119.8M
National Alzheimer's Coordinating CenterU24AG072122 · NIA · UNIVERSITY OF WASHINGTON · PI STEPHENS, KARI A · 2021 to 2025
$45.8M
MVP Data Integration into the ADSP Phenotype Harmonization ConsortiumU24AG074855 · NIA · VANDERBILT UNIVERSITY MEDICAL CENTER · PI CUCCARO, MICHAEL L, HOHMAN, TIMOTHY J · 2021 to 2025
$37.5M
Research Education ComponentP30AG062422 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Gil Dan Rabinovici · 2019 to 2026
$36.9M
Research Education ComponentP30AG062421 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI STEVEN E ARNOLD · 2019 to 2026
$36.5M
UCSD Shiley-Marcos Alzheimer's Disease Research Center P30P30AG062429 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Mark W Bondi · 2019 to 2026
$34.9M
Wisconsin Alzheimer's Disease Research CenterP30AG062715 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Barbara Brigitta Bendlin · 2019 to 2026
$34.5M
Research Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI NILUFER ERTEKIN-TANER · 2019 to 2026
$33.5M
Research Education ComponentP30AG066514 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Carolyn Wei Zhu · 2020 to 2026
$31.0M
Yale Alzheimer Disease Research CenterP30AG066508 · NIA · YALE UNIVERSITY · PI STEPHEN M STRITTMATTER, CHRISTOPHER H VAN DYCK · 2020 to 2026
$30.2M
Research Education CoreP30AG066462 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Miguel Arce · 2020 to 2026
$30.1M
Research Education ComponentP30AG066468 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI C. Elizabeth Shaaban · 2020 to 2026
$29.4M
Alzheimer's Association AACSF-24-1307411Alzheimer's Association AARFD-21-849349Alzheimer's Association F32AG074625Alzheimer's Association P30AG035982Alzheimer's Association P30AG072973Alzheimer's Association R01AG043962Iqbal Farrukh and Asad Jamal FundIqbal Farrukh and Asad Jamal Fund, and Schwab CharitableNIA NIH HHS F32 AG074625NIA NIH HHS K23 AG090733NIA NIH HHS K99 AG071837NIA NIH HHS P20 AG068024NIA NIH HHS P20 AG068053NIA NIH HHS P20 AG068077NIA NIH HHS P20 AG068082NIA NIH HHS P30 AG035982NIA NIH HHS P30 AG062421NIA NIH HHS P30 AG062422NIA NIH HHS P30 AG062429NIA NIH HHS P30 AG062677NIA NIH HHS P30 AG062715NIA NIH HHS P30 AG066444NIA NIH HHS P30 AG066462NIA NIH HHS P30 AG066468NIA NIH HHS P30 AG066506NIA NIH HHS P30 AG066507NIA NIH HHS P30 AG066508NIA NIH HHS P30 AG066509NIA NIH HHS P30 AG066511NIA NIH HHS P30 AG066512NIA NIH HHS P30 AG066514NIA NIH HHS P30 AG066515NIA NIH HHS P30 AG066518NIA NIH HHS P30 AG066519NIA NIH HHS P30 AG066530NIA NIH HHS P30 AG066546NIA NIH HHS P30 AG072931NIA NIH HHS P30 AG072946NIA NIH HHS P30 AG072947NIA NIH HHS P30 AG072958NIA NIH HHS P30 AG072959NIA NIH HHS P30 AG072972NIA NIH HHS P30 AG072973NIA NIH HHS P30 AG072975NIA NIH HHS P30 AG072976NIA NIH HHS P30 AG072977NIA NIH HHS P30 AG072978NIA NIH HHS P30 AG072979NIA NIH HHS P50 AG047366NIA NIH HHS R01 AG043962NIA NIH HHS R01 AG059716NIA NIH HHS R01 AG068193NIA NIH HHS R01 AG079280NIA NIH HHS U01 AG068057NIA NIH HHS U24 AG021886NIA NIH HHS U24 AG067418NIA NIH HHS U24 AG072122NIA NIH HHS U24 AG074855NIH HHS ADSP-PHC U24 AG074855NIH HHS U24 AG021886NIH HHS U24 AG067418NINR NIH HHS ADSP-PHC U24 AG074855
6 · The paper itself

Abstract

introductionAmyloid positron emission tomography (PET) is increasingly available for diagnosis of Alzheimer`s disease (AD); however, its practical implications in heterogenous cohorts are debated.

methodsAmyloid PET from 890 National Alzheimer`s Coordinating Center participants with up to 10 years post-PET follow up was analyzed. Cox proportional hazards and linear mixed models were used to investigate amyloid burden prediction of etiology and prospective functional status and cognitive decline.

resultsAmyloid positivity was associated with progression from unimpaired to mild cognitive impairment and dementia. Amyloid burden in the unimpaired group was associated with lower initial memory levels and faster decline in memory, language, and global cognition. In the Impaired group, amyloid was associated with lower initial levels and faster decline for memory, language, executive function, and global cognition. DISCUSSION: Amyloid burden is an important prognostic marker in a clinically heterogeneous cohort. Future work is needed to establish the proportion of decline driven by AD versus non-AD processes in the context of mixed pathology. HIGHLIGHTS: Our findings highlight the importance of amyloid positron emission tomography (PET) in heterogenous cohorts, including diverse demographics, clinical syndromes, and underlying etiologies. The results also provide evidence that higher amyloid levels were linked to functional progression from unimpaired cognition to mild cognitive impairment (MCI) and from MCI to dementia. In cognitively unimpaired individuals, higher amyloid burden was associated with poorer memory at baseline and subsequent declines in memory, language, and global cognition. Among individuals with cognitive impairment, amyloid burden was associated with worse initial memory, language, executive function, and global cognition, and faster declines over time.

Indexed as

Alzheimer DiseaseAmyloidBrainCognitive DysfunctionPositron-Emission TomographyAgedAged, 80 and overCognitionCohort StudiesDisease ProgressionFemaleHumansLongitudinal StudiesMaleNeuropsychological TestsAmyloidAlzheimer's diseaseamyloid PETneurodegenerative disease heterogeneity

Identifiers

PMID40145384
PMCPMC11947745

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.